PTEN

Genetic and imaging data support the idea that lower-than-usual levels of the tumor suppressor gene PTEN can drive the formation of some ovarian cancers.

The patent application was filed by Montefiore Medical Center's Sanjay Goel and John Mariadason, who discovered the association between mutations in the PIK3CA and PTEN genes and a lack of response to EGFR inhibitors.

Data presented by Myriad at AACR support the "hypothesis that PTEN status predicts outcome after radical prostatectomy, and suggest further, that PTEN may be a clinically important molecular marker for defining aggressive prostate cancer."

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.